Stuttgart - Delayed Quote EUR

Abbott Laboratories (ABL.SG)

Compare
110.38
+0.48
+(0.44%)
At close: January 17 at 4:53:05 PM GMT+1
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
41,217,000.00
40,109,000.00
43,653,000.00
43,075,000.00
34,608,000.00
Cost of Revenue
18,320,000.00
17,975,000.00
19,142,000.00
18,537,000.00
15,003,000.00
Gross Profit
22,897,000.00
22,134,000.00
24,511,000.00
24,538,000.00
19,605,000.00
Operating Expense
16,203,000.00
15,656,000.00
16,149,000.00
16,113,000.00
14,248,000.00
Operating Income
6,694,000.00
6,478,000.00
8,362,000.00
8,425,000.00
5,357,000.00
Net Non Operating Interest Income Expense
-240,000.00
-252,000.00
-375,000.00
-490,000.00
-500,000.00
Other Income Expense
324,000.00
438,000.00
319,000.00
276,000.00
111,000.00
Pretax Income
6,778,000.00
6,664,000.00
8,306,000.00
8,211,000.00
4,968,000.00
Tax Provision
1,011,000.00
941,000.00
1,373,000.00
1,140,000.00
497,000.00
Net Income Common Stockholders
5,767,000.00
5,723,000.00
6,933,000.00
7,071,000.00
4,495,000.00
Diluted NI Available to Com Stockholders
5,767,000.00
5,723,000.00
6,933,000.00
7,071,000.00
4,495,000.00
Basic EPS
3.31
3.30
3.99
4.01
2.54
Diluted EPS
3.29
3.26
3.91
3.94
2.50
Basic Average Shares
1,740,460.50
1,734,076.36
1,737,795.02
1,764,082.19
1,771,230.27
Diluted Average Shares
1,748,520.00
1,749,000.00
1,764,000.00
1,789,000.00
1,786,000.00
Total Operating Income as Reported
6,694,000.00
6,478,000.00
8,362,000.00
8,425,000.00
5,357,000.00
Total Expenses
34,523,000.00
33,631,000.00
35,291,000.00
34,650,000.00
29,251,000.00
Net Income from Continuing & Discontinued Operation
5,767,000.00
5,723,000.00
6,933,000.00
7,071,000.00
4,495,000.00
Normalized Income
5,772,955.89
5,758,219.00
6,934,670.00
7,071,861.00
4,463,800.00
Interest Income
342,000.00
385,000.00
183,000.00
43,000.00
46,000.00
Interest Expense
582,000.00
637,000.00
558,000.00
533,000.00
546,000.00
Net Interest Income
-240,000.00
-252,000.00
-375,000.00
-490,000.00
-500,000.00
EBIT
7,360,000.00
7,301,000.00
8,864,000.00
8,744,000.00
5,514,000.00
EBITDA
10,584,000.00
10,544,000.00
12,131,000.00
12,282,000.00
8,841,000.00
Reconciled Cost of Revenue
16,990,000.00
16,698,000.00
17,888,000.00
17,046,000.00
13,808,000.00
Reconciled Depreciation
3,224,000.00
3,243,000.00
3,267,000.00
3,538,000.00
3,327,000.00
Net Income from Continuing Operation Net Minority Interest
5,767,000.00
5,723,000.00
6,933,000.00
7,071,000.00
4,471,000.00
Total Unusual Items Excluding Goodwill
-7,000.00
-41,000.00
-2,000.00
-1,000.00
8,000.00
Total Unusual Items
-7,000.00
-41,000.00
-2,000.00
-1,000.00
8,000.00
Normalized EBITDA
10,591,000.00
10,585,000.00
12,133,000.00
12,283,000.00
8,833,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-1,044.11
-5,781.00
-330.00
-139.00
800.00
12/31/2020 - 12/28/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

IOB.DU Ion Beam Applications SA
12.98
-2.41%
 
8C4.F CYBERDYNE Inc.
1.0440
-0.19%
 
CYBQF CYBERDYNE Inc.
1.0350
0.00%
 
2SE.F Sequana Medical NV
2.5400
-1.17%
 
NEOLA.ST Neola Medical AB (publ)
2.5400
-0.78%
 
V8Y.SI Quantum Healthcare Limited
0.0020
0.00%
 
2SE.SG Sequana Medical NV
2.5400
-2.68%
 
EPIS-B.ST Episurf Medical AB (publ)
0.1318
-2.23%
 
P09.SG Pacific Biosciences of California Inc
1.5986
+2.46%
 
BIOV.TA Bio-View Ltd
30.20
+4.86%